OmniAb, Inc. (NASDAQ:OABI) CEO Matthew W. Foehr Sells 41,811 Shares

OmniAb, Inc. (NASDAQ:OABI) CEO Matthew W. Foehr sold 41,811 shares of the business’s stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $3.24, for a total transaction of $135,467.64. Following the completion of the transaction, the chief executive officer now owns 3,749,639 shares of the company’s stock, valued at approximately $12,148,830.36. The trade was a 1.10 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

OmniAb Price Performance

Shares of OABI stock opened at $3.20 on Friday. OmniAb, Inc. has a 1 year low of $3.11 and a 1 year high of $6.55. The firm has a fifty day moving average price of $3.64 and a 200-day moving average price of $4.05. The company has a market cap of $451.90 million, a price-to-earnings ratio of -5.16 and a beta of -0.10.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on OABI. Benchmark reiterated a “buy” rating and set a $8.00 target price on shares of OmniAb in a research note on Thursday, November 14th. HC Wainwright reiterated a “buy” rating and set a $11.00 target price on shares of OmniAb in a research note on Thursday, November 14th.

Institutional Investors Weigh In On OmniAb

A number of hedge funds have recently modified their holdings of OABI. American Century Companies Inc. grew its position in shares of OmniAb by 52.7% during the 2nd quarter. American Century Companies Inc. now owns 110,036 shares of the company’s stock valued at $413,000 after acquiring an additional 37,963 shares during the period. Dimensional Fund Advisors LP boosted its holdings in OmniAb by 6.9% in the 2nd quarter. Dimensional Fund Advisors LP now owns 3,012,216 shares of the company’s stock worth $11,296,000 after buying an additional 194,835 shares during the period. Sei Investments Co. boosted its holdings in OmniAb by 11.0% in the 2nd quarter. Sei Investments Co. now owns 29,024 shares of the company’s stock worth $109,000 after buying an additional 2,888 shares during the period. Squarepoint Ops LLC bought a new position in OmniAb in the 2nd quarter worth $449,000. Finally, The Manufacturers Life Insurance Company bought a new position in OmniAb in the 2nd quarter worth $147,000. Institutional investors own 72.08% of the company’s stock.

OmniAb Company Profile

OmniAb, Inc, a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts.